Роль таурина и его дефицита в организме человека и животных

  • Авторы: Анциферов М.Б1,2
  • Учреждения:
    1. Эндокринологический диспансер ДЗ, Москва
    2. ГБУЗ “Эндокринологический диспансер" Департамента здравоохранения г. Москвы
  • Выпуск: № 16 (2012)
  • Страницы: 60-65
  • Раздел: Статьи
  • URL: https://journals.eco-vector.com/2073-4034/article/view/279933
  • ID: 279933

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В представленном обзоре рассматриваются роль таурина в метаболизме, последствия его дефицита и эффекты, которые наблюдаются при устранении недостатка таурина в организме. Обсуждается вклад таурина в профилактику и лечение сахарного диабета и его осложнений, а также в снижение рисков сердечно-сосудистых заболеваний.

Полный текст

Доступ закрыт

Об авторах

М. Б Анциферов

Эндокринологический диспансер ДЗ, Москва; ГБУЗ “Эндокринологический диспансер" Департамента здравоохранения г. Москвы

д.м.н, профессор

Список литературы

  1. Worden J.A., Stipanuk M.H. A comparison by species, age and sex of cysteinesulfinate decarboxylase activity and taurine concentration in liver and brain of animals. Comp Biochem Physiol B 1985; 82(2):233-39.
  2. Kirino Y., Goto Y.-I., Campos Y., Arenas J., Suzuki T. Specific correlation between the wobble modification deficiency in mutant tRNAs and the clinical features of a human mitochondrial disease. Proc Natl Acad Sci USA 2005;102:7127-32.
  3. Suzuki T., Suzuki T., Wada T., Saigo K., Watanabe K. Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases. Embo J 2002;21:6581-89.
  4. Kirino Y., Yasukawa T., Ohta S., et al. Codon-specific translational defect caused by wobble modification deficiency in mutant tRNA from a human mitochondrial disease. Proc Natl Acad Sci USA 2004;101:15070-75.
  5. Schaffer S.W., Azuma J., Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 2009;87:91-9.
  6. Barbeau, Donaldson J. Zinc, taurine, and epilepsy. Archives of Neurology 1974;30(1):52-8.
  7. Sahin M.A., Yucel O., Guler A., et al. is there any cardioprotective role of Taurine during cold ischemic period following global myocardial ischemia? J Cardiothorac Surg 2011;6:31.
  8. Fennessy F.M., Moneley D.S., Wang J.H., et al. Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation 2003; 107(3):410-15.
  9. Chauncey K.B., Tenner T.E., Tenner T.E. The effect of taurine supplementation on patients with type 2 diabetes mellitus. Advances in Experimental Medicine and Biology 2003;526:91-6.
  10. Fujita T., Ando K., Noda H. Y., et al. Effects of increased adrenomedullary activity and taurine in youngpatientswith borderline hypertension. Circulation1987;75(3):525-32.
  11. J. Azuma, A. Sawamura, N. Awata, et al. “Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial,'" Clinical Cardiology 1985;8(5):276-82.
  12. Wilde M.l., Wagstaff A.J. “'Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997;53(6):1038-53.
  13. Getiner M., Sener G., Sener G. Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death. Toxicol Appl Pharmac 2005;209( 1 ):39-50.
  14. Singh R.B., Kartikey K., Charu A.S., et al. Effect of taurine and coenzyme Q10 in patients with acute myocardial infarction. Advances in Experimental Medicine and Biology 2003;526;41-8.
  15. Wallace D.R., Dawson R. Decreased plasma taurine in aged rats. Gerontology 1990;36( 1):19-27.
  16. Barbeau A., Inoue N., Tsukada Y., Butterworth R.F. The neuropharmacology of taurine. Life Sciences 1975;17(5):669-77.
  17. Ярцев Е.И., Гольдберг Е.Д., Колесников Ю.А. Докшина Г.А. Таурин. Фармакологические и противолучевые свойства. М., 1975.
  18. Yamori Y., Liu L., Ikeda K., Miura A., Mizushima S., Miki T., Nara Y. WHO-Cardiovascular Disease and Alimentary Comprarison (CARDIAC) Study Group. Distribution of twenty-four hour urinary taurine excretion and association with ischemic heart disease mortality in 24 populations of 16 countries: results from the WHO-CARDIAC study. Hypertens Res 2001;24(4):453-57.
  19. Yamori Y., Taguchi T., Hamada A., Kunimasa K., Mori H., Mori M. Taurine in health and diseases: consistent evidence from experimental and epidemiological studies. From 17th International Meeting of Taurine Fort Lauderdale, FL, USA. 14-19 December 2009. J Biomed Sci 2010;17(1):6.
  20. Sturman J.A. Taurine in Development. Physiol Rev 1993;73( 1).
  21. Sturman J.A., Cohen P.A., and GaullAULL G.E. Effects of deficiency of vitamin B6 on transsulfuration. Biochem Ann NYAcad Sci модулятора многих патофизиологических процессов в организме человека. Есть основания считать, что достаточное потребление таурина и устранение его дефицита в организме позволят более эффективно бороться со многими хроническими неинфекционными заболеваниями. 1986;477:196-213.
  22. Novotny Mark J., Hogan Patricia M., Flannigan G. Echocardiographic Evidence for Myocardial Failure Induced by Taurine Deficiency in Domestic Cats. Can J Vet Res 1994;58:6-12.
  23. Seghieri G., Tesi F., Bianchi L., Loizzo A., Saccomanni G., Ghirlanda G., Anichini R., Franconi F. Taurine in women with a history of gestational diabetes. Diabetes Res Clin Pract 2006.
  24. Wharton B.A., Morley R., Isaacs E.B., Cole T.J., Lucas A. Low plasma taurine and later neurodevelopment. Archives of Disease in Childhood Fetal and Neonatal Edition 2004;89.
  25. Pasantes-Morales H., Hernandez-Benitez R. Taurine and brain development: trophic or cytoprotective actions? Neurochem Res 2010;35(12):1939-43. Epub 2010 Sep 15.
  26. Jeevanandam M., Young D.H., Ramias L., Schiller W.R. Effect of major trauma on plasma free amino acid concentrations in geriatric patients. Am J Clin Nutr 1990;51(6): 1040-45.
  27. Pion P.D., Kittleson M.D., Thomas W.P., Delellis L.A., Rogers Q.R. Response of cats with dilated cardiomyopathy to taurine supplementation. J Am Vet Med Assoc. 1992 Jul 15;201(2): 275-84.
  28. Welles E.G., Boudreaux M.K., Tyler J.W. Platelet, antithrombin, and fibrinolytic activities in taurine-deficient and taurine-replete cats. Am J Vet Res 1993;54(8):1235-43.
  29. Hayes K.C., Trautwein E.A. Taurine deficiency syndrome in cats. Vet Clin North Am Small Anim Pract 1989;19(3):403-13.
  30. Sanderson S.L. Taurine and carnitine in canine cardiomyopathy. Vet Clin North Am Small Anim Pract 2006;36(6):1325-43.
  31. Kittleson M.D., Keene B., Pion P.D., Loyer C.G. Results of the multicenter spaniel trial (MUST): taurine- and carnitine-responsive dilated cardiomyopathy in American cocker spaniels with decreased plasma taurine concentration. In: J Vet Intern Med 1997;11(4):204-11.
  32. Takashi I., Shohei O., Mika T., Yasushi K., et al. Cardiac and skeletal muscle abnormality in taurine transporter-knockout mice. Ito et al. J Biomed Sci 2010;17(1):20.
  33. Warskulat U., Heller-Stilb B, Oermann E, Zilles K., Haas H., Lang F., Haussinger D. Phenotype of the taurine transporter knockout mouse. Methods Enzymol 2007, 428:439-58.
  34. Huang D.Y., Boini K.M., Lang P.A., Grahammer F. et al. Impaired ability to increase Ito et al. Journal of Biomedical Science 2010, 17(Suppl 1):S20 water excretion in mice lacking the taurine transporter gene TAUT. Pflugers Arch 2006;451:668-77.
  35. Warskulat U., Borsch E., Reinehr R., et al. Chronic liver disease is triggered by taurine transporter knockout in the mouse. Faseb J. 2006;20:574-76.
  36. Ulrich-Merzenich G., Zeitler H., Vetter H., Bhonde R.R. Protective effects of taurine on endothelial cells impaired by high glucose and oxidized low density lipoproteins. Eur J Nutr 2007;46(8):431 -38.
  37. Ito T., Fujio Y., Schaffer S.W., Azuma J. Involvement of transcriptional factor TonEBP in the regulation of the taurine transporter in the cardiomyocyte. Adv Expt Med Biol 2009;643:523-32.
  38. Ito T., Muraoka S., Takahashi K., Fujio Y., Schaffer S.W., Azuma J. Beneficial effect of taurine treatment against doxorubicin-induced cardiotoxicity in mice. Adv Expt Med Biol 2009;643:65-73.
  39. Harada H., Cusack B.J., Olson R.D., Stroo W., et al. Taurine deficiency and doxorubicin: interaction with the cardiac sarcolemmal calcium pump. Biochem Pharm 1980;39:745-51. doi: 10.1016/0006-2952(90)90154-D.
  40. Dgardin J., Pain D., Gondouin P., Simonutti M., et al. Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol Cell Neurosci 2010 April;43(4):414-21.
  41. D'Eufemia P., Finocchiaro R., Celli M., et al. Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate. Biomed Pharmacother 2010;64(4):271-74. Epub 2009 Oct 23.
  42. Das J., Ghosh J., Manna P., Sil P.C. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res 2010;44(3): 340-55.
  43. Chen W., Matuda K., Nishimura N., Yokogoshi H. The effect of taurine on cholesterol degradation in mice fed a high-cholesterol diet. Life Sci 2004;74(15):1889-98.
  44. Chesney R.W., Han X., Patters A.B. Taurine and the renal system. J Biomed Sci. 2010; 17( 1 ):4.
  45. McManus M.L., Hurchwell K.B.C., Trange K.S. Regulation of cell vulume in health and disease. N Engl J Med 1995;333:1260-66.
  46. Lee A.Y., Chung S.S. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999;13:23-30.
  47. Sugiyama K., Kushima Y, Muramatsu K. Effect of methionine, cysteine and taurine on plasma cholesterol level in rats fed a high cholesterol diet. Agric Biol Chem 1984;48:2897-99.
  48. Murakami S., Kondo-Ohta Y., Tomisawa K. Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet. Life Sci 1999;64:83-91.
  49. Hayes K.C., Pronczuk A., Addesa A.E., et al. Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr 1989;49: 1211-16.
  50. Mazzanti L., Rabini R.A., Faloila E., et al. Altered cellular Ca2+ and Na+ transport in diabetes mellitus. Diabetes 1990;39:850-54.
  51. Srivastava S., Joshi C.S., Sethi P.P. et al. Altered platelet functions in non-insulin-dependent diabetes mellitus (NIDDM). Thromb Res 1994;76:451-61.
  52. Zentay Z., Raguwanshi M., Reddi A., et al. Cytosolic Ca profile of resting and thrombin-stimulated platelets from black women with NIDDM. J Diabetes Complications 1995;9:74-80.
  53. Franconi F., Miceli M., Fazzini A., et al. Taurine and diabetes - humans and experimental models. Adv Exp Med Biol 1996; 403:579-82.
  54. Poitout V., Robertson R.P. Minireview: secondary β-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143:339-42.
  55. Han J., Bae J.H., Kim S.Y., et al. Taurine increases glucose sensitivity of UCP2-overexpressing beta-cells by ameliorating mitochondrial metabolism. Am J Physiol Endocr Metab 2004;287(5):E1008-18.
  56. Oprescu A.I., Bikopoulos G., Naassan A., et al. Free Fatty Acid - Induced Reduction in Glucose-Stimulated Insulin Secretion. Diabetes 2007;56:2927-37.
  57. Cherif H., Reusens B., Ahn M.T., et al. Effects of taurine on the insulin secretion of rat islets from dams fed a low-protein diet. J Endocrinol 1998;159:341-48.
  58. Hales C.N., Barker D.J.P. Type 2 (non-insulindependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992;35:595-601.
  59. Nakaya Y., Minami A., Harada N., et al. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am J Clin Nutr 2000;71:54-58.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2012